Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.…
REG - Oxford Nanopore Tech - Grant of LTIP awards; Director/PDMR Notification
Oxford Nanopore Technologies (LON: ONT) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,314 employees.
The shares were at 188.70 GBp on 20 November 2026, up 42.8% over 52 weeks. Its 52-week range is 95.61 GBp to 239.60 GBp: the price is 21.2% below the high and 97.4% above the low.
Its market capitalisation is 1.85B GBP.
Oxford Nanopore Technologies reports return on equity of -31.3%, an operating margin of -46.1% and revenue up 10.5% year over year.
It holds more cash than debt, a net cash position of 143.00M GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 219.92 GBp is 16.5% above the current price. The next earnings report is expected on 3 March 2027.